1. The combination of infectious bronchitis virus BR1 and Mass vaccines provides broad protection.
- Author
-
Bataille, Hanneke, Molenaar, Robert Jan, Schaefer, Gustavo, Zuanaze, Marcelo, and De Wit, Sjaak
- Subjects
- *
AVIAN infectious bronchitis virus , *VACCINE effectiveness , *PHARMACOPOEIAS , *VACCINATION , *VACCINES - Abstract
Two vaccination-challenge trials were performed using a commercial infectious bronchitis virus (IBV) BR1 vaccine, given alone or combined with a commercial IBV Mass vaccine against challenges with IBV M41, 793B, D388 (QX), Q1, Brasil-1 or Variant 2 challenge viruses, which includes the IB viruses that are dominant in South America. The efficacy of the vaccines against the challenge viruses was investigated by determination of the ciliary activity of the tracheal epithelium after challenge. The level of protection induced by the IBV BR1 vaccine alone against the six IBV challenge strains, of which five were of heterologous genotypes, varied from 50% to 100% with an average of 80%. The level of protection induced by the combination of the IBV BR1 and IBV Mass vaccines against the six IBV challenge strains, of which four were of heterologous genotypes, varied from 80% to 100% with an average of 92%. Vaccination with IBV BR1 alone provided a high level of protection against most tested challenge viruses, though the combination of IBV BR1 and IBV Mass was more consistent, showing less variation and compliance with the criterium mentioned in the European Pharmacopoeia 10th edition (at least 80% protection) for all tested challenge viruses. These trials show that vaccination with a combination of IBV BR1 and IBV Mass vaccines provides high levels of protection against the circulating IBV strains in South America. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF